https://ag1343inhibitor.com/se....tup-scientific-disci
As autologous stem-cell transplantation (SCT) remains the standard of care for second-line therapy of many patients with rr-cHL, optimization of second-line regimens by using brentuximab vedotin, or, as time goes on, checkpoint inhibitors, is promising to improve both the qualifications rate for transplant and the last outcome. The necessity for subsequent therapy, and especially allogeneic SCT, is paid down with brentuximab vedotin consolidation for 1 12 months, while pembroli
Like
Comment
Share
